Literature DB >> 22849546

Ten-day sequential versus triple therapy for Helicobacter pylori eradication: a prospective, open-label, randomized trial.

Jun-Won Chung1, Young Kul Jung, Yoon Jae Kim, Kwang Ahn Kwon, Jung Ho Kim, Jong Joon Lee, Sung Min Lee, Ki Baik Hahm, Sun Mi Lee, Jin Yong Jeong, Sung-Cheol Yun.   

Abstract

BACKGROUND AND AIM: Increased resistance of Helicobacter pylori to antibiotics has increased the need to develop new first-line treatments for H. pylori. We have prospectively evaluated 10-day sequential versus conventional triple therapy in peptic ulcer patients.
METHODS: One hundred and fifty-nine patients with peptic ulcer diseases were prospectively randomized to receive 10 days of lansoprazole, amoxicillin, and clarithromycin (conventional triple therapy) or 5 days of lansoprazole and amoxicillin followed by 5 days of lansoprazole, clarithromycin, and metronidazole (sequential therapy). Post-treatment H. pylori status was determined by the (13) C-urea breath test. Eradication rates, antibiotic resistance rates by agar dilution method, drug compliance, and side-effects were compared.
RESULTS: The intention-to-treat eradication rates were 75.9% (95% CI 66.5-85.3%, 60/79) in the sequential therapy group and 58.7% (95% CI 47.9-69.5%, 47/80) in the conventional triple therapy group (P = 0.01), while the per-protocol eradication rates were 86.8% (95% CI 78.7-94.8%, 59/68) and 67.6% (95% CI 56.5-78.7%, 46/68) (P = 0.01), respectively. Compliance and side-effects were similar in the two groups. Culture of H. pylori showed that 18.2% were resistant to clarithromycin, 41.9% to metronidazole. Dual resistance to both antibiotics was 9.6%.
CONCLUSIONS: Although 10-day sequential therapy yielded a higher H. pylori eradication rate than 10-day conventional triple therapy, the sequential therapy protocol did not result in a sufficiently satisfactory eradication rate. This might be related to the higher antibiotics resistance rate especially to dual resistance. More effective regimens are needed to overcome antibiotic resistance in Korea.
© 2012 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22849546     DOI: 10.1111/j.1440-1746.2012.07249.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  22 in total

1.  Sequential therapy versus standard triple therapy in Helicobacter pylori eradication in a high clarithromycin resistance setting.

Authors:  Can Dolapcioglu; Aysun Koc-Yesiltoprak; Emel Ahishali; Aziz Kural; Hatice Dolapcioglu; Aliye Soylu; Resat Dabak
Journal:  Int J Clin Exp Med       Date:  2014-08-15

2.  Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication.

Authors:  Jae Jin Hwang; Dong Ho Lee; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Nayoung Kim
Journal:  World J Gastroenterol       Date:  2015-09-21       Impact factor: 5.742

3.  The impact of bismuth addition to sequential treatment on Helicobacter pylori eradication: A pilot study.

Authors:  Sebahat Basyigit; Ayse Kefeli; Ferdane Sapmaz; Abdullah Ozgür Yeniova; Zeliha Asilturk; Murat Hokkaomeroglu; Metin Uzman; Yasar Nazligul
Journal:  Bosn J Basic Med Sci       Date:  2015-10-25       Impact factor: 3.363

4.  The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy.

Authors:  Sho Suzuki; Takuji Gotoda; Chika Kusano; Kunio Iwatsuka; Mitsuhiko Moriyama
Journal:  Am J Gastroenterol       Date:  2016-05-17       Impact factor: 10.864

5.  Rabeprazole, clarithromycin, and amoxicillin Helicobacter pylori eradication therapy: report of an efficacy study.

Authors:  Charles Asabamaka Onyekwere; Joan Nwabuaku Odiagah; Rufina Igetei; Amancia Olufunmilayo Duro Emanuel; Francis Ekere; Stella Smith
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

Review 6.  Antibiotic treatment for Helicobacter pylori: Is the end coming?

Authors:  Su Young Kim; Duck Joo Choi; Jun-Won Chung
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-11-06

7.  Sequential Therapy for Helicobacter pylori Infection in Korea: Systematic Review and Meta-Analysis.

Authors:  Joon Sung Kim; Byung-Wook Kim; Joo Ho Ham; Hyung Wook Park; Yun Kyeong Kim; Min Young Lee; Jeong-Seon Ji; Bo-In Lee; Hwang Choi
Journal:  Gut Liver       Date:  2013-08-14       Impact factor: 4.519

8.  Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020.

Authors:  Hye-Kyung Jung; Seung Joo Kang; Yong Chan Lee; Hyo-Joon Yang; Seon-Young Park; Cheol Min Shin; Sung Eun Kim; Hyun Chul Lim; Jie-Hyun Kim; Su Youn Nam; Woon Geon Shin; Jae Myung Park; Il Ju Choi; Jae Gyu Kim; Miyoung Choi
Journal:  Korean J Intern Med       Date:  2021-06-08       Impact factor: 2.884

Review 9.  Treatment of Helicobacter pylori Infection in Korea: A Systematic Review and Meta-analysis.

Authors:  Sang Wook Lee; Hyun Jung Kim; Jae Gyu Kim
Journal:  J Korean Med Sci       Date:  2015-07-15       Impact factor: 2.153

Review 10.  Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy.

Authors:  Luigi Gatta; Nimish Vakil; Dino Vaira; Carmelo Scarpignato
Journal:  BMJ       Date:  2013-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.